Fresenius SE Current Ratio 2016-2023 | FSNUY
Current and historical current ratio for Fresenius SE (FSNUY) from 2016 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Fresenius SE current ratio for the three months ending September 30, 2023 was 1.54.
| Fresenius SE Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2023-09-30 |
$48.80B |
$31.77B |
1.54 |
| 2023-06-30 |
$21.05B |
$17.51B |
1.20 |
| 2023-03-31 |
$20.50B |
$17.09B |
1.20 |
| 2022-12-31 |
$19.26B |
$14.39B |
1.34 |
| 2022-09-30 |
$19.58B |
$14.97B |
1.31 |
| 2022-06-30 |
$20.03B |
$15.22B |
1.32 |
| 2022-03-31 |
$20.20B |
$0.39B |
52.03 |
| 2021-12-31 |
$20.66B |
$17.82B |
1.16 |
| 2021-09-30 |
$20.44B |
$18.10B |
1.13 |
| 2021-06-30 |
$20.36B |
$18.32B |
1.11 |
| 2021-03-31 |
$20.13B |
$19.23B |
1.05 |
| 2020-12-31 |
$18.02B |
$15.10B |
1.19 |
| 2020-09-30 |
$19.68B |
$16.20B |
1.22 |
| 2020-06-30 |
$18.89B |
$17.00B |
1.11 |
| 2020-03-31 |
$18.03B |
$17.64B |
1.02 |
| 2019-12-31 |
$17.10B |
$15.55B |
1.10 |
| 2019-09-30 |
$16.88B |
$15.32B |
1.10 |
| 2019-06-30 |
$16.69B |
$15.45B |
1.08 |
| 2019-03-31 |
$16.99B |
$15.53B |
1.09 |
| 2018-12-31 |
$17.47B |
$15.68B |
1.11 |
| 2018-09-30 |
$16.97B |
$15.46B |
1.10 |
| 2018-06-30 |
$17.04B |
$14.46B |
1.18 |
| 2018-03-31 |
$16.48B |
$13.83B |
1.19 |
| 2017-12-31 |
$14.25B |
$12.06B |
1.18 |
| 2017-09-30 |
$15.13B |
$12.51B |
1.21 |
| 2017-06-30 |
$14.08B |
$11.41B |
1.23 |
| 2017-03-31 |
$13.94B |
$10.85B |
1.28 |
| 2016-12-31 |
$13.06B |
$9.46B |
1.38 |
| 2016-09-30 |
$12.32B |
$9.35B |
1.32 |
| 2016-06-30 |
$12.43B |
$9.10B |
1.37 |
| 2016-03-31 |
$11.68B |
$8.16B |
1.43 |
| 2015-12-31 |
$12.12B |
$8.23B |
1.47 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$16.465B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
